Cardiff Oncology, Inc. (CRDF) Stock

Cardiff Oncology, Inc. (CRDF) is a Healthcare stock trading at $0.88 (as of 2026-08-21), with a market capitalization of $68.47M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Understand Cardiff Oncology, Inc.: how it makes money

Cardiff Oncology develops oncology medicines in clinical trials, including onvansertib, CY140, TROV-054, and TROV-053, and it is currently not generating revenue other than $0.0 royalty revenue shown.

With royalty revenue shown at $0.0, the company’s profit model depends on clinical-stage candidates demonstrating meaningful efficacy and advancing toward future commercialization and any resulting royalties.

Revenue by segment (latest quarter)
Royalty	$0.0B

Business quality (Weak): You get a clear view of pipeline and trial efficacy indicators (response rates and progression-free survival metrics), but the latest quarter shows no revenue and a very large operating loss, which is typical for clinical-stage development.

Bull case

On-trial efficacy metrics reported for onvansertib programs: Progression-Free Survival Rate at Six Months is 94.1 percent, and Objective Response Rate is 40.0 percent (with Confirmed Objective Response Rate reported at 72.2 percent).
Favorable progression-free survival comparisons reported: Progression-Free Survival Hazard Ratio Versus Folinic Acid, Fluorouracil, and Irinotecan and Bevacizumab is 0.38, and the other reported hazard ratio comparison is 0.37.

Bear case

No revenue generation in the latest quarter: Revenue for the period ended 2026-03-31 is 0.0B, with royalty revenue shown at 0.0.
Large operating losses typical of early-stage drug development: Operating margin is reported at -31341.5% for the latest quarter.
Efficacy appears weaker in some prior-treatment groups: Overall Response Rate is 77.0 percent in bevacizumab-naive patients, versus 10.0 percent in patients previously exposed to bevacizumab.

Valuation — source: SEC EDGAR (first-party)
Price	$0.88
Market Cap	$68.47M
Price / Book	2.58
Price / Sales	223.75
FCF Yield	-81.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$593000.00
Net Margin	-7732.0%
Revenue Growth (YoY)	-13.2%
EPS Growth (YoY)	-27.4%
FCF Growth (YoY)	0.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-9.29 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($10.46M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Mani Mohindru
Employees	32
Country	US
IPO Date	2004-07-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.